For patients with a history of HER2+ metastatic disease who present with asymptomatic, low-volume, newly diagnosed brain metastases, treatment should be discussed by the MDT incorporating patient values with treatment options including initial HER2-directed systemic therapy versus upfront local therapy (REAL Alliance Expert Opinion). The gene discussed is ERBB2; the disease is metastatic neoplasm.